Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
Tóm tắt
Từ khóa
Tài liệu tham khảo
Baekelandt M, Holm R, Nesland JM, Trope CG, Kristensen GB (2000) Expression of apoptosis - related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol 18: 3775–3781
Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R (1999) Clinical significance of apoptosis - related factors p53, Mdm2, and bcl-2 in advanced ovarian cancer. J Clin Oncol 17: 2061–2068
Barber HR, Sommers SC, Snyder R, Kwon TH (1975) Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol 121: 795–807
Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR (2000) Bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 82: 436–440
Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N (2000) MEK/ERK signaling pathway regulates the expression of bcl-2, bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79: 355–369
Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ (1996) DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971–1981
Christian MC, Trimble EL (1994) Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 55(Suppl): S143–S150
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc 34: 187–220
de Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Sire E, Arzani D, Stanzione S, Parodi S, D'incalci M, Russo P, Broggini M (1997) DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 76: 474–479
DiCioccio RA, Werness BA, Peng R, Allen HJ, Piver MS (1998) Correlation of TP53 mutations and p53 expression in ovarian tumours. Cancer Genet Cytogenet 105: 93–102
Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Lohrs U (1996) Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341–349
Eisenhauer EA, Gore M, Neijt JP (1999) Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 10 (Suppl): S9–S15
Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11: 1217–1228
Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, Blumenson LE (1997) p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80: 892–898
Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russel SE (2001) p53 Mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 194: 68–75
Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G (1999) p53 Overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 81: 733–740
Garrett MD, Workman P (1999) Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 35: 2010–2030
Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W (2000) p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 77: 278–282
Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64–69
Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ (1996) The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178–2184
Hong M, Lai MD, Lin YS, Lai MZ (1999) Antagonism of p53-dependent apoptosis by mitogen signals. Cancer Res 59: 2847–2852
Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C (1998) Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 53: 819–826
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kupryjańczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW (1993) p53 Gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961–4965
Kupryjańczyk J, Dansonka-Mieszkowska A, Szymańska T, Karpińska G, Rembiszewska A, Rusin M, Konopiński R, Kraszewska E, Timorek A, Yandell DW, Stelmachów J (2000) Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction. Br J Cancer 82: 579–583
Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F (2000) p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18: 3936–3945
Makar A, Baekelandt M, Trope CG, Kristensen GB (1995) The prognostic significance of residual disease, figo substage, tumor histology, and grade in patients with figo stage III ovarian cancer. Gynecol Oncol 56: 175–180
Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, Ishii K, Nagata I (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 35: 1214–1219
Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, Kuhn W, Schauer A (1997) Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 17: 2233–2240
Mehta CR, Patel NR (1983) A network algorithm for the exact treatment of Fisher's exact test in RxC contingency tables. J Am Stat Assn 78: 427–434
Miller AB, Hogestraeten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799–1805
Miyashita T, Reed JC (1995) Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299
Partridge EE, Phillips JL, Menck HR (1996) The national cancer data base report on ovarian cancer treatment in United States Hospitals. Cancer 78: 2236–2246
Raffo AJ, Kim AL, Fine RL (2000) Formation of nuclear bax/p53 complexes is associated with chemotherapy induced apoptosis. Oncogene 19: 6216–6228
Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984–2997
Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689–693
Russell P (1994) Surface epithelial-stromal tumours of the ovary. In Blaustein's Pathology of the Female Genital Tract, Kurman RJ. (ed) pp 705–782. Berlin Heidelberg, New York: Springer-Verlag
Ryan KM, Ernst MK, Rice NR, Vousden KH (2000) Role of NF-kappaB in p53–mediated programmed cell death. Nature 404: 892–897
Scheid MP, Duronio V (1998) Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA 95: 7439–7444
Schuyer M, van der Burg MEL, Henzen-Longmans SC, Fieret JH, Klijn JGM, Look MP, Foekens JA, Stoter G, Berns EMJJ (2001) Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85: 1359–1367
Sengupta PS, McGown AT, Bajaj V, Blackhall F, Swindell R, Bromley M, Shanks JH, Ward T, Buckley CH, Reynolds K, Slade RJ, Jayson GC (2000) p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 36: 2317–2328
Shahin MS, Hughes JH, Sood AK, Buller RE (2000) The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89: 2006–2017
Shimada M, Kigawa J, Kanamori Y, Itamochi H, Takahashi M, Kamazawa S, Sato S, Terakawa N (2000) Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts. Eur J Cancer 36: 1869–1875
Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin - induced apoptosis. J Biol Chem 275: 39435–39443